NCT00060645 - Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

May 31, 2006

Study Completion Date

February 28, 2009

Conditions

TumorsLymphomaMultiple Myeloma

Interventions

DRUG

ridaforolimus

There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.

Trial Locations (1)

78229

Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio